Repare Therapeutics, Inc. (RPTX)

NASDAQ: RPTX · IEX Real-Time Price · USD
8.93
0.22 (2.53%)
May 27, 2022 4:00 PM EDT - Market closed
Market Cap384.85M
Revenue (ttm)7.84M
Net Income (ttm)-120.25M
Shares Out43.10M
EPS (ttm)-3.08
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume118,886
Open8.76
Previous Close8.71
Day's Range8.47 - 9.17
52-Week Range8.07 - 35.75
Betan/a
AnalystsBuy
Price Target38.87 (+335.3%)
Earnings DateMay 12, 2022

About RPTX

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related...

IndustryBiotechnology
IPO DateJun 19, 2020
Employees158
Stock ExchangeNASDAQ
Ticker SymbolRPTX
Full Company Profile

Financial Performance

In 2021, RPTX's revenue was $7.60 million, an increase of 5,529.63% compared to the previous year's $135,000. Losses were -$106.91 million, 100.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for RPTX stock is "Buy." The 12-month stock price forecast is 38.87, which is an increase of 335.27% from the latest price.

Price Target
$38.87
(335.27% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of it...

2 weeks ago - Business Wire

Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 6.74% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results f...

3 weeks ago - Business Wire

Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibit...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that preclinical d...

1 month ago - Business Wire

Repare Therapeutics Inc. (RPTX) Stock Jumps 9.1%: Will It Continue to Soar?

Repare Therapeutics Inc. (RPTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the...

1 month ago - Zacks Investment Research

Repare Therapeutics Shares Dip After Updated RP-3500 Data In Solid Tumors

Repare Therapeutics Inc (NASDAQ: RPTX) presented updated data from its ongoing Phase 1/2 TRESR trial of RP-3500 for solid tumors with specific synthetic-lethal genomic alterations. The data were feature...

1 month ago - Benzinga

Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in S...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today presented updated data from ...

1 month ago - Business Wire

Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it has been select...

1 month ago - Business Wire

Repare Therapeutics to Present Comprehensive Phase 1 Monotherapy Data From the Phase 1/2 TRESR RP-3500 Clinical Trial...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary syntheti...

2 months ago - Business Wire

Repare Therapeutics Presents RP-3500 Dose Selection Phase 1 Monotherapy Safety Data from the Phase 1/2 TRESR Clinical...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary syntheti...

2 months ago - Business Wire

Repare Therapeutics Inc. (RPTX) Reports Q4 Loss, Tops Revenue Estimates

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 6.67% and 94.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary syntheti...

2 months ago - Business Wire

Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary syntheti...

3 months ago - Business Wire

Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary syntheti...

4 months ago - Business Wire

Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New P...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of...

4 months ago - Business Wire

Repare Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary syntheti...

4 months ago - Business Wire

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306 in Combination with Gemcitabine for the ...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary syntheti...

5 months ago - Business Wire

Repare Therapeutics Insiders Establish New and Modified Automatic Securities Disposition Plans

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary syntheti...

5 months ago - Business Wire

Repare Therapeutics Inc. (RPTX) Reports Q3 Loss, Tops Revenue Estimates

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -18.57% and 39.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the s...

6 months ago - Zacks Investment Research

Repare Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary syntheti...

6 months ago - Business Wire

Repare Therapeutics Announces Closing of Upsized Offering of Common Shares and Full Exercise of Underwriters' Option ...

CAMBRIDGE, Mass. & MONTREAL, Québec--(BUSINESS WIRE)--Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discove...

6 months ago - Business Wire

Repare Therapeutics Announces Pricing of Upsized Offering of Common Shares

CAMBRIDGE, Mass. & MONTREAL, Quebec--(BUSINESS WIRE)--Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discove...

7 months ago - Business Wire

Repare Therapeutics Announces Proposed Public Offering of Common Shares

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and d...

7 months ago - Business Wire

Repare Therapeutics to Participate at the H.C. Wainwright 2nd Annual Precision Oncology Conference

CAMBRIDGE, Mass. & MONTREAL, Quebec--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that membe...

7 months ago - Business Wire

Repare Therapeutics Reveals Early Efficacy Data From Lead Program In Solid Tumor Setting

Repare Therapeutics Inc (NASDAQ: RPTX) announced the presentation of preliminary Phase 1 monotherapy data from its Phase 1/2 TRESR trial of RP-3500 for solid tumors with specific synthetic-lethal genomi...

7 months ago - Benzinga